Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib + Caelyx in Advanced HER2+ Breast Cancer
NCT02131506Phase 1Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Dec 2009
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lapatinib in breast cancer, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Maximum Tolerated Dose at 6 years. Started Dec 2009; status: terminated.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02131506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02131506.